West Sweden Artificial Intelligence – An Inspirational Map
West Sweden – Artificial Intelligence – An Inspiration Introduction Åsa Lindström, Sahlgrenska Science Park Erik Behm, Business Region Göteborg Inspirational Map of Big Data, Machine Learning & AI Johan Hogsved, haw & co Inspirational Map of AI in Life Science Petra Apell, Aproficio AB The Map Selected Industries, Companies & Actors Next Steps
West Sweden – Inspirational Map of Big Data, Machine Learning & AI
Disclosures Petra Apell 26 years of experience from Pharma, MedTech & BioTech. M.Sc Chemistry, Gothenburg University. PhD student, Chalmers University of Technology. Serial entrepreneur. Current ventures: 10MD and Aproficio. AI experience is somewhat limited. Extensive experience from applying new technologies, e.g. eHealth and Virtual Reality, in medical applications. Working as a consultant for Sahlgrenska Science Park. Disclosures Johan Hogsved 20 years of experience in combining Tech, Business & Leadership. M.Sc. Engineering Physics, B.Sc. Business Administration. I run a company in IT-development & management consulting and a startup in robotic automation. Working as a consultant for Business Region Göteborg.
The Mission Create an map featuring West Sweden actors in the Big Data, Machine Learning & AI arena ”Is it possible to find 100 companies and organisations in the Gothenburg Area only ?”
Definitions used here Big Data: The use of predictive analytics, user behavior analytics, or certain other advanced data analytics methods that extract value from data. Machine Learning: A field of computer science that gives computers the ability to learn without being explicitly programmed. Artificial Intelligence: When a machine mimics "cognitive" functions that humans associate with other human minds, such as "learning" and "problem solving ”.
What we laughed at in 2014…
Where we are today …
BIG DATA, MACHINE LEARNING & AI INSPIRATIONAL MAP – WEST SWEDEN 2018 Transport & Automotive Financial & ERP Other verticals Internet & Security Life Science Applications (verticals) Incubators & Arenas Research & Education Service Partners
Volvo Cars - Innovation in Transportation
Volvo Trucks - Innovation in Transportation
AI LANDSCAPE – TRANSPORT & AUTOMOTIVE ” Our work is about where Veoneer’s ambition is to For Volvo Cars, technology Our company originates should make people’s lives the technology meets the from the safety leaders of be a leading system easier. That’s why our customer benefit. As a the automotive industry. We supplier for ADAS and approach to autonomous starting point, we look at are young as a company but autonomous driving as driving is all about the the demands put on our starting point builds on well as a market leader people that will use them. customers by their robust industrial automotive in automotive safety customers. We are focused solutions. electronics products. Our future cars will be able on solutions that can make to navigate without human We have a unique skillset Veoneer has the difficult, repetitive and time- world’s broadest input, equipped with from Tier 1 and OEM consuming tasks easier for sensors that read the domain knowledge. All the automotive safety all concerned .” surroundings, adapting to way from sensors to vehicle product portfolio, changing traffic conditions. control. comprised of state-of- Hayder Wokil the-art active safety We have joined forces to Autonomous & Automated systems, restraint create an independent Driving Director, control systems, and company offering our Volvo Truck brake systems. passion, technology, and solutions.
Recorded Future - Innovation in Cyber Security
AI LANDSCAPE – INTERNET & SECURITY ”The world’s premier ”To err is human, they You need more than just Halon consists of a platform for accumulating say. But in the security internal network data to dedicated team of doers. knowledge business, the goal is a uncover evolving and Together we have set out to and building intelligence ” zero fail rate, something stealthy threats. change the landscape of nobody comes closer to email technology, by A revolutionary, open and than Irisity .” enabling service providers modular digital We believe machine to tailor their perfect email Irisity’s solution: To investigation software used learning combined with infrastructure. by national combine Artificial human expertise is security, defense and law Intelligence and unrivaled at scaling the enforcement agencies Machine Learning and delivery of contextualized around the world. couple it with vigilant threat intelligence. human input.
AI is getting ready for healthcare. But is healthcare ready for AI?
Traditional life science players are active in digitization Our newly appointed Chief Digital Officer will help us GSK has consistently been active in the digital transform our business model using digital technologies. To space, most recently looking to apply AI to drug improve the way we use data in drug discovery and discovery and medical device mobile apps. The development, engage with patients, doctors and other impact of technology on the healthcare industry is stakeholders. And automate our business processes. accelerating and requires us to rethink our Jim Jimenez, CEO Novartis approach. Emma Walmsley, CEO GSK Through advanced tools like machine learning, we can understand which individualized therapies will be the most effective for improving quality of life, reducing healthcare costs, and preventing relapse and remission in specific segments of the population — all the way down to individualized care. Stuart McGuigan, CIO, J&J
AI can create value across the value chain Product & service User experience R&D - Drug discovery - Diagnosis - Supply & distribution - Drug Design - Product portfolio - Patient support - Clinical trials - Decision support - Education
Approach to analyzing AI adoption levels in West Sweden Main purpose Identify companies that address AI opportunities or apply AI technologies. Secondary purpose Catalyse the continued development of AI related life science projects. Methods Sources: www, innovation system, funding agencies, EU applications, network, virtual communities, public reports, newspapers, etc. Interviews: 10 senior developers and managers. Adoption level: 1 = Corporate strategy to address AI opportunities. 3 = Partial AI adopters or experimenters. 5 = AI adopters with proactive strategy and implemented solutions.
Life Science NOTE: List may not be complete, new companies are continuously added. List contains companies engaged on different levels.
AI used in a variety of applications across the value chain 11% 11% Drug discovery & design 16% Product / service Diagnostics Education Decision support 38% Patient support 11% 13%
AI adoption level per application 5 AI adopters with 100%� proactive strategy and implemented solutions 80%� 3 Partial AI adopters or experimenters 60%� 40%� 1 Corporate strategy to address AI opportunities 20%� 0%� Drug discovery Product / Diagnostics Education Decision Patient support & design service support
Identified challenges • Start-ups who might have the technology, might not have access to data. • Which data sets are the most important ones? • Structure and annotate data. • Ownership of data - patient or company? • Complexity is a limiting factor • Sometimes difficult to show return on investment (ROI). • Regulatory – clash between the dynamic and the traditional approach.
Integrative Research Laboratories Peder Svensson, Dir Comp Chem & Biol, CIO
Drug discovery – the dominating picture Human pathophysiology Animal models In silico drug design. Ex vivo models Virtual HTS Cell-based assays Big Data & AI Binding assays High throughput screening (HTS)
ISP - a useful complement in drug discovery Human pathophysiology Computational modelling at all stages, including AI methods Animal models In silico drug design Ex vivo models Cell-based assays Starting point Binding assays
Computational modelling including AI methods Support for idea generation, Quantitative Structure-Activity Relationships (QSAR) Design of experiments / compound selection Visualization and interpretationof data Systems pharmacological translational modelling using physiologically relevant, uniform and comparable data of high quality
Artificial arms get closer to the real thing Integrum has developed new breakthrough technology to connect bionic prostheses to the patient’s bone, nerves, and muscles. Robotic prostheses controlled via implanted neuromuscular interfaces have become a clinical reality thanks to Integrum’s osseointegrated technology. Founders: “ We have used osseointegration to create a long-term Per-Ingvar Brånemark & Richard Brånemark stable fusion between man and machine ” Max Ortiz Catalan, Chalmers University of Technology.
INCREASE VALUE AND LIMIT RISK IN R&D PROJECTS AND PORTFOLIOS
Recommend
More recommend
